Eleva, a manufacturer of superior biologics, is entering clinical phases with 
its own drug candidates, such as immune-regulating factor H, as well as in 
collaboration with pharmaceutical partners. Its moss-based platform is ideally 
suited to produce difficult-to-express but therapeutically promising drug 
candidates. 

Its recently expanded production capacity enables Eleva to conduct clinical 
studies of its drug candidates. Among the first ones is factor H which will be 
developed through phase II. Up to 2,500 l will be produced in state-of-the-art 
single-use reactors at a GMP site. 

Eleva's moss-based platform offers unique advantages for recombinant protein 
development, such as: 

- Moss glycostructure naturally lacks core á-1,6 fucose – a known allergen – 
while any other glycans can be "humanized". This leads to excellent organ 
uptake. 
- Being a plant, it will not be contaminated with animal pathogens, which 
eliminates the need for antibiotics. 
- The moss production system, haploid by nature, is based on an intact 
organism, not on cell cultures. This guarantees exceptionally stable 
modifications. 

Eleva is leveraging those advantages to produce complex proteins for future 
therapies, such as 2nd generation oncological therapeutics, or 
virus-like-particles (VLP) for vaccine development. 

Ralf Smit, CBO of Eleva: "With production scaling up, we can now offer to 
develop difficult-to-express therapeutic proteins in collaboration with 
partners in the pharmaceutical industry. We look forward to our moss platform 
unlocking the very promising potential of complex candidates for the benefit of 
patients."

About Eleva
Based in Freiburg, Germany, Eleva develops novel biological therapies with its 
pharmaceutical partners. The privately-held company leverages its unique 
moss-based production platform to produce supreme biologics like antibodies, 
replacement enzymes, or fusion toxins. Eleva has successfully developed drug 
candidates into clinical phases.

Press contact 
eleva GmbH
Fabienne Zeitter 
pr@elevabiologics.com 
Phone: +49 761 470 990
www.elevabiologics.com 

Source: eleva GmbH